Target Name: SPAG16
NCBI ID: G79582
Review Report on SPAG16 Target / Biomarker Content of Review Report on SPAG16 Target / Biomarker
SPAG16
Other Name(s): Sperm-associated WD repeat protein | PF20 | WD repeat domain 29 | pf20 protein homolog | Pf20 protein homolog | WDR29 | SPG16_HUMAN | FLJ37717 | sperm associated antigen 16 | MGC87036 | Sperm-associated antigen 16 protein (isoform 1) | sperm-associated WD repeat protein | Sperm associated antigen 16, transcript variant 1 | DKFZp666P1710 | SPAG16 variant 1 | FLJ22724 | Sperm-associated antigen 16 protein

SPAG16: A Potential Drug Target and Biomarker

SPAG16, or Sperm-associated WD repeat protein, is a protein that is expressed in high levels in the sperm of many organisms, including humans. It is a member of the WD repeat family of proteins, which are characterized by a specific repeat sequence that is conserved across various species. While SPAG16 has been studied extensively for its role in various biological processes, its potential drug target and biomarker properties have yet to be fully explored.

SPAG16 functions as a negative regulator of gene expression, which means that when a gene is expressed, SPAG16 will prevent it from being translated into protein. This mechanism of gene regulation is important for maintaining tissue homeostasis and for ensuring that only necessary proteins are produced. SPAG16 has been shown to play a role in the regulation of gene expression in various organisms, including bacteria, yeast, and plants.

SPAG16 has also been shown to be involved in the regulation of protein stability and interactions. In one study, SPAG16 was shown to interact with the protein Fyn, which is involved in the regulation of protein stability and degradation. This interaction between SPAG16 and Fyn suggests that SPAG16 may be a potential drug target for diseases that are characterized by the misregulation of protein stability and interactions.

SPAG16 has also been shown to be involved in the regulation of cellular processes that are important for maintaining tissue homeostasis, such as cell adhesion and migration. In one study, SPAG16 was shown to be involved in the regulation of tight junction formation in epithelial cells, which is important for maintaining tissue barrier function. This suggests that SPAG16 may be a potential drug target for diseases that are characterized by the disruption of tissue homeostasis.

SPAG16 is also expressed in various tissues and organs, including the brain, heart, and liver. This suggests that it may be a potential biomarker for a variety of diseases, including neurodegenerative diseases, cardiovascular diseases, and liver diseases. In addition, the fact that SPAG16 is expressed in high levels in the sperm highlights its potential as a drug target for male-related diseases, such as male infertility or androgen-dependent diseases.

In conclusion, SPAG16 is a protein that has been extensively studied for its role in various biological processes, including gene regulation, protein stability and interactions, and cellular processes that are important for maintaining tissue homeostasis. Its potential drug target and biomarker properties make it an attractive target for further research and development. Further studies are needed to fully explore the functions of SPAG16 and its potential as a drug target and biomarker.

Protein Name: Sperm Associated Antigen 16

Functions: Necessary for sperm flagellar function. Plays a role in motile ciliogenesis. May help to recruit STK36 to the cilium or apical surface of the cell to initiate subsequent steps of construction of the central pair apparatus of motile cilia (By similarity)

The "SPAG16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPAG16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SPAG16-DT | SPAG17 | SPAG4 | SPAG5 | SPAG5-AS1 | SPAG6 | SPAG7 | SPAG8 | SPAG9 | SPAM1 | SPANXA1 | SPANXA2-OT1 | SPANXB1 | SPANXB2 | SPANXC | SPANXD | SPANXN1 | SPANXN2 | SPANXN3 | SPANXN4 | SPANXN5 | SPARC | SPARCL1 | SPART | SPART-AS1 | SPAST | SPATA1 | SPATA12 | SPATA13 | SPATA13-AS1 | SPATA16 | SPATA17 | SPATA18 | SPATA19 | SPATA2 | SPATA20 | SPATA20P1 | SPATA21 | SPATA22 | SPATA24 | SPATA25 | SPATA2L | SPATA3 | SPATA3-AS1 | SPATA31A1 | SPATA31A2 | SPATA31A3 | SPATA31A5 | SPATA31A6 | SPATA31A7 | SPATA31C1 | SPATA31C2 | SPATA31D1 | SPATA31D3 | SPATA31E1 | SPATA32 | SPATA33 | SPATA4 | SPATA41 | SPATA42 | SPATA45 | SPATA46 | SPATA48 | SPATA5 | SPATA5L1 | SPATA6 | SPATA6L | SPATA7 | SPATA8 | SPATA8-AS1 | SPATA9 | SPATC1 | SPATC1L | SPATS1 | SPATS2 | SPATS2L | SPC24 | SPC25 | SPCS1 | SPCS2 | SPCS2P4 | SPCS3 | SPDEF | SPDL1 | SPDYA | SPDYC | SPDYE1 | SPDYE18 | SPDYE2 | SPDYE21 | SPDYE2B | SPDYE3 | SPDYE4 | SPDYE5 | SPDYE6 | SPDYE7P | SPDYE8 | SPDYE9 | SPECC1 | SPECC1L